SRSF2 and myelodysplastic syndrome: TET2 and SRSF2 mutations were enriched in CMML patients [44% (53/121) and 32% (39/121), respectively], and 20% (24/121) of the CMML patients had both TET2/SRSF2 mutations, a significantly frequent compared with the rest of MDS/MPN patients [2% (2/91) of the MDSMPN-U/RARS-T patients, P < 0.00001].